Baird Downgrades Ra Pharma (RARX) to Neutral Following Acquisition
Tweet
Share
E-mail
Get Alerts RARX Hot Sheet
Price: $48.00 --0%
Rating Summary:
0 Buy, 9 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 4 | New: 9
Rating Summary:
0 Buy, 9 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 4 | New: 9
Join SI Premium – FREE
Baird analyst Madhu Kumar downgraded Ra Pharma (NASDAQ: RARX) from Outperform to Neutral with a price target of $48.00 (from $38.00).
For an analyst ratings summary and ratings history on Ra Pharma click here. For more ratings news on Ra Pharma click here.
Shares of Ra Pharma closed at $22.69 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ICICI Securities Downgrades Manappuram Finance Ltd (MGFL:IN) to Hold (3)
- JPMorgan Upgrades Amber Enterprises India Ltd (AMBER:IN) to Overweight
- Northcoast Downgrades Brinker Int'l (EAT) to Neutral
Create E-mail Alert Related Categories
DowngradesRelated Entities
Robert W BairdSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
